Memory B cell

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day

Retrieved on: 
Thursday, March 9, 2023
Vaccine, Cancer, Biotechnology, Developing country, RNA, GLB, Therapy, Standard of care, Outline, RNEC, GRNA, EpiVax, Shingles, Green-light, Bladder cancer, Memory B cell, Health, Agriculture, COVID-19, Infection, Vaccination, Messenger, COVID, Fine chemical

-- R&D Day webcast to begin at 10:30 am ET today

Key Points: 
  • GreenLight today is sharing the key pillars of its human health strategy:
    Developing vaccines for infectious diseases, especially those addressing unmet medical needs in lower- and middle- income countries.
  • Consistent with its public benefit corporation status, GreenLight is striving to support global, sustainable vaccine access and pandemic response readiness.
  • GreenLight has selected a lead candidate to progress towards clinical development after evaluation of multiple antigen designs and formulations.
  • “We continue to be excited about expediting the development of personalized cancer vaccines in collaboration with EpiVax Therapeutics.” Kimberly Warren, Chief Business Officer of GreenLight Biosciences.

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, NIH, Lists of diseases, Bacteria, Vaccine, Memory B cell, Program, Infection, Review, Technology, Commissariat, BCG, Antigen, Radiobiology, Forward-looking statement, Investment, Ministry of Social Affairs, Ministry, Iliad, Medical research, Private Securities Litigation Reform Act, Moral and National Education controversy, Environment, Whooping cough, Fast track (FDA), Disease, Lists of publishing companies, National Institute of Allergy and Infectious Diseases, Tuberculosis, Medicine, Behavior, Twitter, WHO, TB, National, Bharath Institute of Higher Education and Research, Industry, Virus, Pasteur Institute, Cancer, Link, CEA, Genomics, Pasteur Institute of Lille, Person, NIAID, Parasitism, Bordetella pertussis, Innovation, National Institute, Diabetes, Degenerative disease, Pharmaceutical industry, Research, Biology, Health

ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.

Key Points: 
  • ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.
  • B-Tech Vector Platform vaccines have demonstrated immunogenicity in 8 peer-reviewed published pre-clinical studies targeting viruses, bacteria, and parasites.
  • In addition to preclinical development of B-Tech Vector vaccines for TB and other targets, ILiAD continues to advance its BPZE1 pertussis vaccine through late-stage clinical development.
  • ILiAD Biotechnologies is utilizing its B-Tech technology to develop next generation vaccines to prevent infectious diseases and improve lives.

DGAP-News: CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Retrieved on: 
Monday, November 22, 2021
Pfizer–BioNTech COVID-19 vaccine, CureVac, Memory B cell, Protein, Technology, LNP, BioRxiv, MD, Severe acute respiratory syndrome coronavirus 2, CVAC, Beth Israel Deaconess Medical Center, Doctor of Philosophy, Vaccine, Vaccination, COVID-19, Animal, GSK, Nasdaq, RNA, RNA transfection, Infection, Degenerative disease, CureVac COVID-19 vaccine, SM-102, the Study, CV2CoV, CureVac, THE STUDY, CV2COV, CUREVAC

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Key Points: 
  • CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
    The issuer is solely responsible for the content of this announcement.
  • The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech).
  • The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach.
  • This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole.

DGAP-News: CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

Retrieved on: 
Tuesday, August 17, 2021
Memory B cell, Interest, Severe acute respiratory syndrome coronavirus 2, SM-102, Technology, Protein, CureVac COVID-19 vaccine, BioRxiv, CVAC, Nasdaq, RNA, Primate, Vaccine, Animal, Antibody, Alpha, Clinical trial, RNA transfection, Infection, Variant, Manuscript, Head, Partnership, LNP, GSK, Kappa, COVID-19, Degenerative disease, Pharmaceutical industry, CV2CoV, CureVac, CV2COV, CUREVAC

CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

Key Points: 
  • CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
    The issuer is solely responsible for the content of this announcement.
  • The study assessed cynomolgus macaques vaccinated with 12g of either the first or second-generation vaccine candidate.
  • Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants.
  • The strong immune response and protection in pre-clinical testing of this second-generation mRNA backbone are very encouraging and represent an important milestone for its further development."